TMG-123 Phase 2 study

Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Exploratory Study of TMG-123 in Patients with Type 2 Diabetes Mellitus

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223642

Enrollment

Registered

2017-09-05

Start date

2017-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : TMG-123 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Subjects with type 1 diabetes , gestational diabetes, or diabetes due to other specific mechanisms or diseases Subjects judged as not eligible by the investigator or sub-investigators for other reasons

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c levels at 12 weeks after the start of drug administration	—

Secondary

Measure	Time frame
Changes in glucose related parameters at 12 weeks and 24 weeks, Safety, PK	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026